Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
NCT06080841

Curcumin Supplementation in Cervical Cancer

Led by National Institute of Cancerología · Updated on 2025-05-25

30

Participants Needed

1

Research Sites

149 weeks

Total Duration

On this page

Sponsors

N

National Institute of Cancerología

Lead Sponsor

S

Sabinsa Corporation

Collaborating Sponsor

AI-Summary

What this Trial Is About

Brief Summary. The goal of this pilot study is to learn about the effect of curcumin supplementation in locally advanced cervical cancer patients. The main questions it aims to answer are: * Does curcumin supplementation increase the levels of p53 and apoptosis in tumor cells from cervical cancer patients? * At which dose of curcumin supplementation is the broader effect observed for p53 expression and apoptosis in tumor cells from cervical cancer patients? * Are all doses safe for supplementation? Participants will be asked to take curcumin tablets throughout their cancer treatment. Researchers will compare 6 different groups, each group will receive a different dose of curcumin with or without piperin, to see the dose with the broader effect and safety of curcumin supplementation: 1. 1 g of curcumin 2. 1 g of curcumin + piperine 3. 3 g of curcumin 4. 3 g of curcumin + piperine 5. 6 g of curcumin 6. 6 g of curcumin + piperine

CONDITIONS

Official Title

Curcumin Supplementation in Cervical Cancer

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Understanding the nature of the study and providing written consent
  • Women older than 18 years
  • ECOG performance status between 0 and 2
  • Willing and able to follow scheduled visits, treatment plans, and lab tests
  • Diagnosed with histological cervical cancer (squamous cell, adenosquamous, adenocarcinoma, or glassy cell carcinoma)
  • Clinical stage IB3 to IVA (FIGO 2018)
  • Eligible for concomitant chemoradiotherapy followed by brachytherapy
  • Measurable disease by imaging (CT, MRI, or PET-CT) according to RECIST v1.1 criteria
  • No prior chemoradiotherapy treatment
  • Hemoglobin level of at least 10 g/dL
  • Leukocyte count of at least 4000/mm3
  • Platelet count of at least 100,000/mm3
  • Adequate liver function
Not Eligible

You will not qualify if you...

  • Receiving nutritional treatment or dietary supplements containing turmeric, ginger, or related spices
  • Having uncontrolled illnesses or active infections that prevent chemotherapy
  • Receiving an experimental drug treatment simultaneously
  • Diagnosed with vesicovaginal or vesicorectal fistula
  • Having previous or other cancers except non-melanoma skin cancer

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Instituto Nacional de Cancerología

Mexico City, Mexico City, Mexico, 14080

Actively Recruiting

Loading map...

Research Team

D

Denisse Castro-Eguiluz, RDN, PhD

CONTACT

A

Alejandro García Carrancá, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

6

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here